Original articleApremilast, an oral phosphodiesterase 4 (PDE4) inhibitor, in patients with moderate to severe plaque psoriasis: Results of a phase III, randomized, controlled trial (Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis [ESTEEM] 1)
Presented at the 72nd Annual Meeting of the American Academy of Dermatology in Denver, Colorado, on March 21-25, 2014 (oral presentation), and at the 71st Annual Meeting of the American Academy of Dermatology in Miami Beach, Florida, on March 1-5, 2013 (poster).
Under a Creative Commons license
open access
Key words
apremilast
clinical trial
ESTEEM
phosphodiesterase 4 inhibitor
psoriasis
treatment
Abbreviations used
AE
adverse event
ESTEEM
Efficacy and Safety Trial Evaluating the Effects of Apremilast in Psoriasis
FDA
Food and Drug Administration
IL
interleukin
PASI
Psoriasis Area and Severity Index
PASI-75
75% or greater reduction from baseline Psoriasis Area and Severity Index score
PDE4
phosphodiesterase 4
SAE
serious adverse event
sPGA
static Physician Global Assessment
Th
T helper
Cited by (0)
This study was sponsored by Celgene Corporation.
Author disclosures are available at the end of the article.
Reprints not available from the authors.
Copyright © 2015 American Academy of Dermatology, Inc. Published by Mosby, Inc.